Skin & Anti-Aging

Palmitoyl Tetrapeptide-7

A palmitoylated Gly-Gln-Pro-Arg peptide that suppresses inflammatory cytokines (IL-6, IL-8) and stimulates collagen production, reducing photoageing and chronic skin inflammation.

C₃₀H₅₆N₆O₆Half-life: Topical; local actionMolar mass: 600.80 g/mol

⚠ Research & Educational Use Only. Palmitoyl Tetrapeptide-7 is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.

Medically reviewed by Dr. Amanda Reid, MDWritten by the KnowYourPeptide Research TeamLast updated April 2026
Our editorial standards →
Key Takeaways
  • Reduces interleukin-6 (IL-6) production - a key driver of chronic skin inflammation and photoageing
  • Inhibits IL-8 (CXCL8) - reduces inflammatory cascade activation in UV-damaged skin
  • Stimulates hyaluronic acid synthesis - improves skin hydration and plumpness
  • Palmitoyl Tetrapeptide-7 is not FDA-approved for human use. Cosmetic ingredient. Approved for topical cosmetic use globally.

Research At a Glance

  • Reduces interleukin-6 (IL-6) production - a key driver of chronic skin inflammation and photoageing
  • Inhibits IL-8 (CXCL8) - reduces inflammatory cascade activation in UV-damaged skin
  • Stimulates hyaluronic acid synthesis - improves skin hydration and plumpness
  • Promotes collagen I, III, and IV synthesis - rebuilds dermis structure

What is Palmitoyl Tetrapeptide-7?

Palmitoyl Tetrapeptide-7 (INCI: palmitoyl tetrapeptide-7; peptide sequence: Gly-Gln-Pro-Arg, N-terminally palmitoylated) is a lipopeptide developed by Sederma (France) as a skin-targeted anti-inflammatory and anti-ageing signal peptide. It is one of the key components in the Matrixyl 3000 complex, where it is formulated alongside Palmitoyl Tripeptide-1 (Pal-GHK).

The peptide operates through a mechanism distinct from pure collagen-stimulating peptides: it suppresses inflammatory cytokine production in keratinocytes and dermal fibroblasts. Specifically, Palmitoyl Tetrapeptide-7 reduces production of IL-6 (interleukin-6) and IL-8 (interleukin-8), two cytokines that are chronically elevated in photoaged, UV-damaged, and environmentally stressed skin. This chronic low-grade inflammation - sometimes called "inflammageing" - is now recognised as a major contributor to accelerated skin ageing, collagen degradation, and impaired barrier function.

By dampening this inflammatory signalling, Palmitoyl Tetrapeptide-7 addresses a root cause of photoageing rather than simply stimulating new collagen production. When combined with collagen-stimulating peptides like Matrixyl (which works via the TGF-beta and messenger peptide pathways to upregulate collagen synthesis), the result is a dual approach: reduce the inflammatory damage driving collagen breakdown while simultaneously stimulating new collagen production.

The palmitoyl (C16 fatty acid) modification at the N-terminus is the standard approach for improving the skin penetration of hydrophilic peptides. Peptides alone are poorly absorbed through the stratum corneum; the lipophilic palmitoyl chain increases affinity for the lipid-rich stratum corneum, improving penetration to the viable epidermis and dermis where the target cells reside.

Research into Palmitoyl Tetrapeptide-7 has also documented effects on hyaluronic acid synthesis - the naturally occurring polysaccharide responsible for skin hydration and volume. Hyaluronic acid production declines with age and UV exposure, contributing to skin thinning and dehydration. The combined stimulation of HA synthesis, collagen production, and IL-6/IL-8 suppression makes Palmitoyl Tetrapeptide-7 a genuinely multi-mechanism anti-ageing peptide.

Key Research Benefits

Documented effects observed in preclinical and clinical studies on Palmitoyl Tetrapeptide-7. See all Skin & Anti-Aging peptides for comparison.

Reduces interleukin-6 (IL-6) production - a key driver of chronic skin inflammation and photoageing
Inhibits IL-8 (CXCL8) - reduces inflammatory cascade activation in UV-damaged skin
Stimulates hyaluronic acid synthesis - improves skin hydration and plumpness
Promotes collagen I, III, and IV synthesis - rebuilds dermis structure
Reduces the appearance of fine lines and wrinkles through combined anti-inflammatory and matrix-building effects
Particularly effective for sun-damaged, inflamed, or rosacea-prone skin
Compatible with Matrixyl and other matrix peptides for synergistic anti-ageing effects
Helps counter glycation-related skin ageing by modulating AGE receptor pathways

Common Stacks

Palmitoyl Tetrapeptide-7 is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.

Kisspeptin drives GnRH release while gonadorelin provides the downstream GnRH signal - used together in HPG axis restoration research.

Gonadorelin profile

Kisspeptin activates the reproductive HPG axis while PT-141 drives central sexual arousal - targeting different dimensions of sexual health.

PT-141 profile

Side Effects & Risks

Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports.

Rarely causes adverse reactions - well tolerated even in sensitive skin types
Occasional mild redness in very sensitive individuals
No systemic absorption concerns at topical concentrations

Dosing Data from the Literature

Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.

Research Dosing Protocol

Palmitoyl Tetrapeptide-7 is used topically at 2-5 ppm (parts per million) in formulations. This low effective concentration is characteristic of signal peptides.

Topical concentration: 2-5 ppm Application: once to twice daily, after cleansing Often formulated with Matrixyl (Palmitoyl Pentapeptide-4) and other anti-ageing peptides in combination serums

Enter your vial size and target dose to get the exact injection volume.

Administration in Research Settings

Standard reconstitution and administration methodology for laboratory research use.

Apply topical formulation to cleansed skin. Gently massage into face, neck, and any areas of chronic inflammation or photoageing. Allow to absorb before applying heavier moisturisers or sunscreen. Use consistently morning and evening for best results.

Explore Further

Quick Reference

Half-Life
Topical; local action
Molar Mass
600.80 g/mol
Formula
C₃₀H₅₆N₆O₆
Legal Status
Cosmetic ingredient. Approved for topical cosmetic use globally.
Storage
Store below 25 degrees C, away from direct light. Stable in aqueous formulations at pH 4-7.

Research Use Only

This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.